Your browser doesn't support javascript.
loading
The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People.
Andrew, Melissa K; Shinde, Vivek; Ye, Lingyun; Hatchette, Todd; Haguinet, François; Dos Santos, Gael; McElhaney, Janet E; Ambrose, Ardith; Boivin, Guy; Bowie, William; Chit, Ayman; ElSherif, May; Green, Karen; Halperin, Scott; Ibarguchi, Barbara; Johnstone, Jennie; Katz, Kevin; Langley, Joanne; Leblanc, Jason; Loeb, Mark; MacKinnon-Cameron, Donna; McCarthy, Anne; McGeer, Allison; Powis, Jeff; Richardson, David; Semret, Makeda; Stiver, Grant; Trottier, Sylvie; Valiquette, Louis; Webster, Duncan; McNeil, Shelly A.
Afiliación
  • Andrew MK; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • Shinde V; GlaxoSmithKline (GSK), King of Prussia, Pennsylvania.
  • Ye L; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • Hatchette T; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • Haguinet F; GlaxoSmithKline (GSK), King of Prussia, Pennsylvania.
  • Dos Santos G; Business and Decision Life Sciences, Bruxelles, Belgium.
  • McElhaney JE; Health Sciences North Research Institute, Sudbury, Ontario.
  • Ambrose A; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • Boivin G; Centre Hospitalier Universitaire de Québec, Quebec City.
  • Bowie W; University of British Columbia, Vancouver, Canada.
  • Chit A; Sanofi Pasteur, Swiftwater, Pennsylvania.
  • ElSherif M; Leslie Dan Faculty of Pharmacy, University of Toronto.
  • Green K; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • Halperin S; Mount Sinai Hospital, Toronto.
  • Ibarguchi B; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • Johnstone J; GSK Vaccines, Mississauga.
  • Katz K; McMaster University, Hamilton.
  • Langley J; North York General Hospital, Toronto.
  • Leblanc J; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • Loeb M; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • MacKinnon-Cameron D; McMaster University, Hamilton.
  • McCarthy A; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax.
  • McGeer A; The Ottawa Hospital.
  • Powis J; Mount Sinai Hospital, Toronto.
  • Richardson D; Michael Garron Hospital, Toronto.
  • Semret M; William Osler Health System, Brampton, Ontario.
  • Stiver G; McGill University, Montreal.
  • Trottier S; University of British Columbia, Vancouver, Canada.
  • Valiquette L; Centre Hospitalier Universitaire de Québec, Quebec City.
  • Webster D; Université de Sherbrooke, Sherbrooke, Quebec.
  • McNeil SA; Horizon Health, Saint John, New Brunswick, Canada.
J Infect Dis ; 216(4): 405-414, 2017 08 15.
Article en En | MEDLINE | ID: mdl-28931244
ABSTRACT

Background:

Influenza is an important cause of morbidity and mortality among older adults. Even so, effectiveness of influenza vaccine for older adults has been reported to be lower than for younger adults, and the impact of frailty on vaccine effectiveness (VE) and outcomes is uncertain. We aimed to study VE against influenza hospitalization in older adults, focusing on the impact of frailty.

Methods:

We report VE of trivalent influenza vaccine (TIV) in people ≥65 years of age hospitalized during the 2011-2012 influenza season using a multicenter, prospective, test-negative case-control design. A validated frailty index (FI) was used to measure frailty.

Results:

Three hundred twenty cases and 564 controls (mean age, 80.6 and 78.7 years, respectively) were enrolled. Cases had higher baseline frailty than controls (P = .006). In the fully adjusted model, VE against influenza hospitalization was 58.0% (95% confidence interval [CI], 34.2%-73.2%). The contribution of frailty was important; adjusting for frailty alone yielded a VE estimate of 58.7% (95% CI, 36.2%-73.2%). VE was 77.6% among nonfrail older adults and declined as frailty increased.

Conclusions:

Despite commonly held views that VE is poor in older adults, we found that TIV provided good protection against influenza hospitalization in older adults who were not frail, though VE diminished as frailty increased. Clinical Trials Registration NCT01517191.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Anciano Frágil / Gripe Humana / Potencia de la Vacuna / Hospitalización Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: J Infect Dis Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Anciano Frágil / Gripe Humana / Potencia de la Vacuna / Hospitalización Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: J Infect Dis Año: 2017 Tipo del documento: Article